Krystal Biotech Soars: RBC Capital Markets Sees Billions in Gene Therapy Potential

There's a palpable buzz surrounding Krystal Biotech (KRYS) this week, especially after RBC Capital Markets, with analyst Lisa Walter at the helm, officially initiated coverage with a very bullish "Outperform" rating. Not just that, they've set a rather ambitious $400 price target, a clear sign of serious confidence in the company's future trajectory. This exciting news broke just this past Friday, August 14, 2026, and has certainly put Krystal Biotech squarely on many investors' radars.

Much of this optimism, it seems, is anchored in Vyjuvek, Krystal Biotech's lead product. This isn't just any treatment; it's a truly innovative, redosable gene therapy designed to tackle Dystrophic Epidermolysis Bullosa (DEB), a terribly rare and debilitating blistering condition. Lisa Walter isn't just hopeful for Vyjuvek; she's projecting a substantial $1 billion in peak sales by 2033. That's a massive figure, underscoring its potential to capture over 60% of the total addressable market for DEB within the United States alone.

And Vyjuvek's impact isn't confined to U.S. borders. The therapy is already making its presence felt internationally, with overseas launches having commenced in the third quarter of 2025. This global reach further solidifies its position as a significant revenue driver and a transformative treatment for patients worldwide, truly demonstrating Krystal Biotech's expansive vision.

But wait, there's more to Krystal Biotech's story than just Vyjuvek. The company's pipeline boasts KB801, an experimental ocular therapy. This promising candidate is aimed at Neurotrophic Keratitis, another rare and serious eye disorder. If Vyjuvek's projections sound impressive, then KB801's are truly staggering: Walter anticipates an even more substantial $2.1 billion in peak sales for this therapy, potentially reaching that milestone as early as 2030. That kind of potential, if realized, would be nothing short of revolutionary.

Now, while the enthusiasm for KB801 is certainly warranted, it's crucial to approach it with a balanced perspective. RBC analyst Lisa Walter, quite rightly, adds a note of caution, highlighting that there's "only 1 positive clinical data point to rely on" at the time of the report. This isn't to dampen spirits, but rather to acknowledge that while the potential is immense, KB801 is still in earlier stages compared to Vyjuvek, and further clinical validation will be key to realizing its full promise.

So, what's next for KB801? Investors won't have to wait indefinitely for more clarity. Near-term clinical data readouts are anticipated in the latter half of 2026, offering crucial updates. Even more significantly, a pivotal readout – a major milestone that could significantly de-risk the asset – is expected in early 2027. These upcoming events will undoubtedly be closely watched catalysts for Krystal Biotech.

In essence, RBC Capital Markets' take paints a very compelling, albeit nuanced, picture for Krystal Biotech. With Vyjuvek establishing a strong foundation and KB801 holding out the promise of even greater returns, the company appears poised for significant growth. It seems the future could be exceptionally bright for this innovative gene therapy pioneer, making it a name definitely worth watching.